Gene interactions and pathways from curated databases and text-mining

◀ Back to CCL2

CCL2 — ITGAM

Pathways - manually collected, often from reviews:

  • OpenBEL Selventa BEL large corpus: Complex of ICAM1-ITGAM-ITGB2 → CCL2 (increases)
    Evidence: Strong adhesion between leukocytes and endothelial cells is promoted by the induction of ICAM-1 on inflamed endothelium and the activation of a conformational change in LFA-1 and Mac-1 in response to chemokines.

Text-mined interactions from Literome

Biswas et al., J Interferon Cytokine Res 2002 : In vitro activation of murine peritoneal macrophages by monocyte chemoattractant protein-1 : upregulation of CD11b , production of proinflammatory cytokines, and the signal transduction pathway
Jiang et al., J Immunol 1992 : We found that MCP-1 induced expression of CD11c ( p150,95 alpha-subunit ) and CD11b ( Mac-1 alpha-subunit ), and caused little or no change of CD11a ( lymphocyte function associated Ag-1 alpha-subunit ), very late activation Ag-4, or leukocyte adhesion molecule-1
Dogan et al., J Immunol 2008 (Disease Models, Animal...) : Furthermore, CNS production of CCL2 resulted in the accumulation of iNOS producing CD11b ( + ) CD11c ( + ) dendritic cells and TNF producing macrophages important for demyelination
Tieu et al., J Clin Invest 2009 (Aneurysm, Dissecting...) : In vitro, coculture of monocytes and aortic adventitial fibroblasts produced MCP-1- and IL-6 enriched conditioned medium that promoted differentiation of monocytes into macrophages, induced CD14 and CD11b upregulation, and induced MCP-1 and MMP-9 expression
Lee et al., Magn Reson Med 2010 : Increased expression of messenger ribonucleic acid ( mRNA ) and expression of CCR2 and CD11b on the cellular surface, as induced by monocyte chemoattractant protein-1, was shown, and the effect of monocyte chemoattractant protein-1 on CCR2 and CD11b was restricted by the CCR2 antagonist
Zhao et al., Hepatology 2013 (Colorectal Neoplasms...) : Inhibition of CCL2 signaling and absence of its cognate receptor CCR2 reduced CD11b/Gr1 ( mid ) recruitment and decreased tumor burden